Matisse Capital Ascendis Pharma A/S Transaction History

Matisse Capital

$206 Million
Q2 2025

A detailed history of Matisse Capital transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Matisse Capital holds 27,942 shares of ASND stock, worth $5.47 Million. This represents 2.35% of its overall portfolio holdings.

Number of Shares

27,942

Previous 29,674 5.84%

Holding current value

$5.47 Million

Previous $4.62 Million 4.28%

% of portfolio

2.35%

Previous 2.51%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$137.41 - $179.1 $237,994 - $310,201	-1,732 Reduced 5.84%	27,942 $4.82 Million
Q1 2025 Apr 24, 2025	SELL	$119.49 - $168.84 $98,220 - $138,786	-822 Reduced 2.7%	29,674 $4.62 Million
Q4 2024 Jan 24, 2025	SELL	$122.0 - $146.6 $388,936 - $467,360	-3,188 Reduced 9.46%	30,496 $4.2 Million
Q3 2024 Oct 17, 2024	SELL	$113.0 - $153.43 $118,085 - $160,334	-1,045 Reduced 3.01%	33,684 $5.03 Million
Q2 2024 Jul 30, 2024	SELL	$121.07 - $153.67 $98,187 - $124,626	-811 Reduced 2.28%	34,729 $4.74 Million
Q1 2024 Apr 30, 2024	BUY	$123.45 - $159.4 $111,722 - $144,257	905 Added 2.61%	35,540 $5.37 Million
Q4 2023 Feb 08, 2024	BUY	$86.1 - $127.36 $721,518 - $1.07 Million	8,380 Added 31.92%	34,635 $4.36 Million
Q3 2023 Oct 13, 2023	SELL	$86.5 - $103.97 $492,617 - $592,109	-5,695 Reduced 17.82%	26,255 $2.46 Million
Q2 2023 Aug 02, 2023	BUY	$69.96 - $97.84 $265,848 - $371,792	3,800 Added 13.5%	31,950 $2.85 Million
Q1 2023 Apr 27, 2023	SELL	$104.9 - $126.78 $248,613 - $300,468	-2,370 Reduced 7.77%	28,150 $3.02 Million
Q4 2022 Jan 20, 2023	BUY	$99.42 - $131.97 $508,036 - $674,366	5,110 Added 20.11%	30,520 $3.73 Million
Q2 2022 Jul 28, 2022	BUY	$78.08 - $117.61 $46,848 - $70,566	600 Added 2.42%	25,410 $2.36 Million
Q1 2022 Apr 12, 2022	BUY	$102.18 - $135.75 $99,114 - $131,677	970 Added 4.07%	24,810 $2.91 Million
Q4 2021 Feb 04, 2022	BUY	$127.1 - $169.66 $499,503 - $666,763	3,930 Added 19.74%	23,840 $3.21 Million
Q3 2021 Nov 08, 2021	BUY	$112.67 - $176.92 $92,389 - $145,074	820 Added 4.3%	19,910 $3.17 Million
Q2 2021 Aug 11, 2021	SELL	$121.62 - $145.29 $133,782 - $159,819	-1,100 Reduced 5.45%	19,090 $2.51 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $341,031 - $473,190	2,730 Added 15.64%	20,190 $2.6 Million
Q4 2020 Feb 12, 2021	BUY	$151.2 - $182.76 $196,559 - $237,588	1,300 Added 8.04%	17,460 $2.91 Million
Q3 2020 Nov 04, 2020	BUY	$134.29 - $154.32 $335,725 - $385,800	2,500 Added 18.3%	16,160 $2.49 Million
Q2 2020 Jul 28, 2020	BUY	$110.87 - $156.01 $166,305 - $234,015	1,500 Added 12.34%	13,660 $2.02 Million
Q1 2020 May 07, 2020	BUY	$97.01 - $145.11 $116,412 - $174,132	1,200 Added 10.95%	12,160 $1.37 Million
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $39,323 - $59,821	430 Added 4.08%	10,960 $1.53 Million
Q3 2019 Oct 28, 2019	BUY	$95.8 - $118.9 $47,900 - $59,450	500 Added 4.99%	10,530 $1.01 Million
Q2 2019 Aug 13, 2019	SELL	$107.11 - $132.09 $10,711 - $13,209	-100 Reduced 0.99%	10,030 $1.16 Million
Q1 2019 Apr 24, 2019	BUY	$62.15 - $129.99 $211,310 - $441,966	3,400 Added 50.52%	10,130 $1.19 Million
Q4 2018 Jan 18, 2019	SELL	$55.16 - $69.67 $253,735 - $320,482	-4,600 Reduced 40.6%	6,730 $422,000
Q3 2018 Oct 30, 2018	SELL	$63.77 - $76.28 $189,396 - $226,551	-2,970 Reduced 20.77%	11,330 $803,000
Q2 2018 Jul 13, 2018	BUY	$58.55 - $73.92 $304,460 - $384,384	5,200 Added 57.14%	14,300 $951,000
Q1 2018 Apr 30, 2018	SELL	$38.98 - $68.04 $116,550 - $203,439	-2,990 Reduced 24.73%	9,100 $595,000
Q4 2017 Jan 30, 2018	BUY	$31.98 - $40.38 $111,930 - $141,330	3,500 Added 40.75%	12,090 $484,000
Q2 2017 Aug 08, 2017	BUY	N/A	8,590	8,590 $238,000

Others Institutions Holding ASND

# of Institutions

280

Shares Held

61.6M

Call Options Held

202K

Put Options Held

201K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $10.9B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

News

Stay updated on Matisse Capital with notifications on news.

Account